Aspirin in Older Adults Linked to Higher Cancer Deaths

For generations, aspirin has been treated as a simple, dependable ally in the fight against heart disease and even cancer. Doctors once advised millions of people to take a daily low-dose tablet, convinced that the benefits outweighed the risks. But new long-term research into its effects on older adults is challenging that long-standing belief and prompting a rethink of preventive medicine in later life.

A major study following generally healthy adults aged 70 and above for nearly a decade found that daily low-dose aspirin did not reduce the overall incidence of cancer. Instead, researchers observed a troubling pattern – people assigned to aspirin during the trial were more likely to die from cancer than those who were not taking it. The findings stand in stark contrast to earlier studies in middle-aged adults, where prolonged aspirin use appeared to lower the risk of certain cancers, particularly colorectal cancer, after many years of continuous treatment.

The results suggest that timing may matter more than previously thought. Aspirin’s protective effects seem to emerge only when the drug is taken for long periods before cancers begin to form. When introduced later in life, the drug may encounter cancers that are already developing. Rather than preventing them, aspirin could alter their progression in ways that are not yet fully understood. Some researchers suspect it may accelerate the spread of certain tumours in older patients, though the biological mechanisms remain unclear.

Age itself may also play a role. As people grow older, their immune systems weaken and their bodies respond differently to inflammation. Aspirin’s anti-platelet and anti-inflammatory properties, once considered universally beneficial, may interact with these age-related changes in ways that undermine the body’s natural defences against cancer. At the same time, the drug’s well-known risk of internal bleeding becomes more significant in older adults, potentially complicating treatment or recovery when serious illness occurs.

The findings are already influencing medical advice. Many health authorities now recommend against routine aspirin use for primary prevention in people over 70 who have no history of heart attack or stroke. The emphasis is shifting from blanket recommendations to more individualised decisions based on a person’s specific health risks.

For older adults, the most immediate solution is caution. Aspirin should no longer be taken casually or out of habit. Those who started the drug years ago without a clear medical reason are being encouraged to consult their doctors before continuing. However, aspirin remains an essential treatment for people who have already suffered cardiovascular events, and stopping it without medical supervision could be dangerous.

Experts are also urging a renewed focus on prevention strategies that have consistently proven effective. Avoiding tobacco, limiting alcohol, maintaining a healthy weight, staying physically active and eating a balanced diet remain the strongest defences against many cancers. Regular screening and early detection programmes are also far more reliable in reducing cancer deaths than any single pill.

The new evidence does not suggest that aspirin is inherently dangerous. Rather, it underscores a broader lesson in modern medicine – treatments that work at one stage of life may not offer the same benefits at another. What was once promoted as a near-universal preventive remedy is now being recast as a targeted therapy, best used only when the advantages clearly outweigh the risks.

For older adults and their doctors, the message is increasingly clear. The decision to take a daily aspirin should no longer be routine. It should be deliberate, personalised and based on the best available evidence, not on the reassuring simplicity of a pill that once seemed to promise protection for all.

Effect of Aspirin on All-Cause Mortality in the Healthy Elderly

Photo – fizkes / Shutterstock